NYSE$NEUE

NeueHealth Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

NeueHealth reported strong results driven by coordinated, consumer-centric care and strong partnerships.

NeueHealth reported a revenue of $245.1 million and a net income from continuing operations of $5.7 million for Q1 2024. The company is maintaining its expectation for 2024 Adjusted EBITDA of between $15 million and $25 million.

  • Delivered Revenue of $245.1 million in Q1 2024.
  • Reported Net Income from Continuing Operations of $5.7 million in Q1 2024.
  • Achieved Adjusted EBITDA of $2.5 million in Q1 2024.
  • NeueCare and NeueSolutions segments are positioned for continued strong performance in 2024.

Headline financials

Total Revenue

$245M

Previous: $756M-67.6%
EPS

-$3.53

Previous: -$14.40+75.5%
Operating Cost Ratio

27.2%

No prior period
Value-Based Consumers served

360.0K

No prior period
Enablement Services Lives

109.0K

No prior period
Capital Expenditures

-$64K

Previous: -$1.86M+96.6%
Free Cash Flow

-$48.8M

Previous: -$617M+92.1%
Net Income

-$15.9M

Previous: -$175M+90.9%
Operating Income

-$23.1M

Previous: -$85.7M+73.1%
Gross Profit

$178M

Previous: $756M-76.4%
Cash & Equivalents

$113M

Previous: $383M-70.5%
Total Assets

$1.11B

Previous: $4.85B-77.2%
Stock-Based Comp

$18.6M

Previous: $33.3M-44.1%

Revenue & EPS history

NeueHealth · Revenue · Quarterly

$245M

Q1 2024-67.6%vs Q1 2023
Beat estimate in 2 of 7 quarters(29%)
ActualEstimate

Forward guidance

For 2024, NeueHealth expects revenue of approximately $1 billion, with NeueCare revenue between $310 million and $320 million, and NeueSolutions revenue between $690 million and $700 million. Adjusted EBITDA is expected to be between $15 million and $25 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-2.0%

Avg return

Earnings day

-6.9%

Avg return

5 days after

-17.7%

Avg return

30 days after

45%

10 / 22 earnings

Positive

+46.5%

Q1 2023

Best reaction

-43.1%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025+0.0%-2.2%-2.1%
Q1 2025-2.2%-0.4%-1.5%
Q4 2024+8.9%+30.9%+29.9%
Q3 2024+2.2%+2.5%+7.8%
Q2 2024-3.6%+2.3%-4.4%
Q1 2024-4.0%-3.7%-14.3%
Q4 2023+7.6%-6.0%-27.7%
Q3 2023-1.5%-10.2%-15.5%
Q2 2023-21.8%-27.8%-61.3%
Q1 2023+46.5%+7.2%-14.1%
Q4 2022-43.1%-48.8%-77.2%
Q3 2022+4.3%-3.7%-15.3%
Q2 2022-9.3%+2.1%-15.1%
Q1 2022+35.7%+26.0%-0.6%
Q4 2019-2.6%-1.3%-16.4%
Q4 2021-29.5%-42.9%-35.6%
Q3 2020+1.3%-13.1%-15.4%
Q3 2021-35.1%-34.4%-40.5%
Q2 2020+5.1%
Q1 2021+5.1%
Q4 2020+5.1%
Q2 2021-13.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro